Snoretox wins the 2025 Innovation Award at the Animal Health Summit in Kansas city
Posted: 6 October 2025 Snoretox has won the Emerging Company Innovation Award at the global Veterinarian new products conference KCAnimalHealth Summit in the USA. This convention is the leading deal-making convention for veterinary pharmaceutical companies in the USA,…
Chimeric Therapeutics reports tumour reduction in CHM CDH17 Phase 1/2 trial
Posted: 30 September 2025 Chimeric Therapeutics announced further evidence of disease control and tumour shrinkage in its CHM CDH17 Phase 1/2 clinical trial, following confirmation by the Safety Monitoring Committee that Dose Level 2 is safe for additional…
University of Melbourne awarded $9 million for three new NHMRC Centres of Research Excellence
Posted: 29 September 2025 The University of Melbourne was awarded $9 million in funding for three new Centres of Research Excellence (CREs), designed to address pressing health and sustainability challenges. The funding, announced by the Minister for Health…
RMIT’s 3D-printed diamond titanium device to power next generation implants
Posted: 29 September 2025 RMIT University researchers announced the development of an experimental 3D-printed diamond–titanium device that generated electricity from flowing liquid and wirelessly received power through tissue, allowing remote monitoring of changes in flow. The innovation was…
Monash University partners with South Korea’s K-Bio Lab Hub to establish first Australian biotech launchpad
Posted: 29 September 2025 Monash University announced a new Memorandum of Understanding (MoU) with South Korea’s government-backed biotech incubator, K-Bio Lab Hub, to create the organisation’s first Australian launchpad in Melbourne. The collaboration, centred within the Monash Technology…
Cureator allocates $15.7 million to advance dementia and cognitive decline innovations
Posted: 25 September 2025 The Brandon Capital managed Cureator, in partnership with ANDHealth and Dementia Australia, confirmed the allocation of $15,765,871 to seven companies developing medical technologies for dementia and cognitive decline. The initiative was supported by the…
Starpharma secures $855 million cancer therapy partnership with Genentech
Posted: 25 September 2025 Starpharma announced a landmark global licensing agreement with Genentech, a Roche Group company, to advance cancer treatments using its proprietary DEP® drug delivery platform. The collaboration provided Starpharma with an upfront payment of USD…
CBE Pure Solutions receives TGA licence to manufacture sterile clinical trial liquids for Phase 2 and 3 clinical trials
Posted: 24 September 2025 CBE Pure Solutions has received expanded licence from the Therapeutic Goods Administration (TGA). Their TGA licence now includes sterile fill-and-finish and labelling for injectables and infusions for all clinical trial phases (1-3). In addition,…
BioMelbourne Network’s Modernising clinical trials BioSymposium explores execution, access and impact for new directions in the clinical trials sector
Posted: 17 September 2025 With the theatrette at Melbourne Museum filled with around 150 curious and eager-to-learn attendees generating lively discussions, the second BioMelbourne Network BioSymposium of 2025, ‘Modernising clinical trials: Execution, access and impact’, brought the sector…
Stephens Lawyers & Consultants release guidance on protecting confidential information and trade secrets in Australia
Posted: 17 September 2025 Stephens Lawyers & Consultants recently released an article examining how confidential information and trade secrets are protected under Australian law . The publication emphasised that these assets can easily lose value if improperly disclosed,…
WEHI team awarded 2025 Eureka Prize for Parkinson’s disease research
Posted: 17 September 2025 A research team from WEHI’s Parkinson’s Disease Research Centre was awarded the 2025 Eureka Prize for Scientific Research for discoveries that revealed how a key protein linked to early-onset Parkinson’s disease functions. The Eureka…
Oncology One, Pfizer, WEHI, Cancer Therapeutics CRC and partners advance Australian-discovered KAT6 inhibitor into Phase 3 breast cancer trial
Posted: 17 September 2025 Oncology One Pty Ltd reported that Pfizer Inc’s clinical candidate PF-07248144, a first-in-class KAT6 inhibitor originating from Australian research, had entered a Phase 3 clinical trial for hormone receptor positive, HER2-negative breast cancer. PF-07248144…
